Acute Myeloid Leukemia Treatment in Gurgaon, Haryana

Overview of Acute Myeloid Leukemia Treatment

Gurgaon has been established as a leading destination for advanced leukemia care, with Artemis Hospitals standing at the forefront of AML diagnosis and treatment in the region. Our hospital is home to a highly experienced team of hematologists, oncologists, and transplant specialists who bring decades of collective expertise in managing complex blood cancers. Artemis is equipped with state-of-the-art diagnostic infrastructure — including advanced flow cytometry, next-generation molecular sequencing, and precision cytogenetic analysis — ensuring every patient receives an accurate diagnosis and a treatment plan tailored to their disease's unique genetic profile. 

Quick Facts About Acute Myeloid Leukemia

What is Acute Myeloid Leukemia (AML)?

Acute Myeloid Leukemia is a fast-moving cancer of the blood and bone marrow in which the body begins producing large numbers of abnormal, immature white blood cells called blasts. These leukemic cells rapidly crowd out healthy blood cells, leaving the body unable to fight infections, carry oxygen, or control bleeding. This creates a dangerous cascade of complications — severe anemia, life-threatening infections, and uncontrolled bleeding — that can deteriorate quickly without treatment. AML is indeed a deadly disease; without prompt intervention, it can be fatal within weeks to months of onset. 

Symptoms of Acute Myeloid Leukemia

The symptoms of AML arise because leukemic cells overwhelm the bone marrow, disrupting the production of normal blood cells. These symptoms can develop suddenly and worsen rapidly, often mimicking other common illnesses which can delay diagnosis. Recognizing both the early and advanced warning signs is essential for seeking timely medical attention. 

Common Symptoms

These are typically the first signs patients notice and are directly linked to the shortage of healthy blood cells in the body. 

• Persistent fatigue and weakness

• Frequent infections and prolonged fever

• Easy bruising and unusual bleeding

• Pale or sallow skin

• Shortness of breath

• Petechiae 

Advanced Symptoms

These symptoms suggest the disease has progressed significantly and the leukemia may be spreading beyond the bone marrow. 

• Bone and joint pain

• Swollen abdomen

• Swollen lymph nodes

• Rapid and unexplained weight loss

• Neurological symptoms

• Gum swelling and overgrowth (gingival hyperplasia)

What are the Causes & Risk Factors of Acute Myeloid Leukemia?

The exact cause of AML is not always identifiable, but the disease originates from acquired genetic mutations in immature myeloid cells that cause them to grow and divide uncontrollably rather than develop into healthy blood cells.

These mutations can occur spontaneously or be triggered by a combination of biological, environmental, and medical factors. Certain risk factors are known to significantly increase a person's likelihood of developing AML.

• Advancing age is one of the strongest — AML is most commonly diagnosed in adults over 60, though it can occur at any age.

• Prolonged exposure to high doses of radiation or certain industrial chemicals, particularly benzene found in petroleum products and cigarette smoke, is strongly associated with AML development.

• A prior history of other blood disorders such as myelodysplastic syndrome (MDS) or myeloproliferative neoplasms considerably raises the risk of progression to AML.

• Previous treatment with certain chemotherapy drugs — particularly alkylating agents and topoisomerase II inhibitors — can also damage DNA in ways that lead to leukemia years later.

• Genetic conditions such as Down syndrome, Fanconi anemia, and Li-Fraumeni syndrome are also recognized risk factors, as are certain inherited mutations that compromise the integrity of DNA repair mechanisms.

What are the Types of Acute Myeloid Leukemia?

AML is not a single uniform disease — it encompasses several distinct subtypes that differ in their origin, underlying biology, behavior, and response to treatment. Understanding the type of AML a patient has is essential for determining the most appropriate and effective treatment strategy. The three primary categories based on disease origin are outlined below. 

De Novo AML

De novo AML is the most common form of the disease and refers to AML that arises spontaneously — meaning it develops on its own without any identifiable preceding blood disorder or prior exposure to leukemia-causing treatments. The term "de novo" is Latin for "from the beginning," reflecting the fact that this type appears without a clear predisposing condition. It can occur across all age groups but is more frequently seen in younger and middle-aged adults. Because it arises fresh rather than evolving from a pre-existing condition, de novo AML often responds better to standard induction chemotherapy compared to other types, and certain subtypes carry favorable genetic profiles that are associated with improved outcomes. 

Secondary AML

Secondary AML develops as a progression or transformation from a pre-existing blood disorder, most commonly myelodysplastic syndrome (MDS), myeloproliferative neoplasms, or aplastic anemia. In these conditions, the bone marrow is already dysfunctional, and over time the accumulating genetic damage causes the disease to evolve into full-blown leukemia. Secondary AML tends to affect older patients who have been living with a chronic blood condition and is generally considered more difficult to treat than de novo AML. It is frequently associated with complex chromosomal abnormalities and an overall poorer prognosis, as the leukemia cells often show greater resistance to standard chemotherapy regimens. Treatment typically requires more aggressive strategies, and allogeneic stem cell transplantation is often considered early in eligible patients. 

Therapy-Related AML

Therapy-related AML (t-AML) is a direct consequence of previous cancer treatment — specifically chemotherapy or radiation therapy administered for an entirely different cancer diagnosis. It is essentially a late complication of cancer survivorship, arising months to years after the original treatment has concluded. The chemotherapy agents most commonly implicated include alkylating agents such as cyclophosphamide and melphalan, as well as topoisomerase II inhibitors like etoposide, both of which can cause DNA damage that eventually triggers leukemic transformation. Therapy-related AML is considered one of the most challenging subtypes to treat, carrying a significantly poorer prognosis than both de novo and secondary AML. The leukemia cells are often resistant to conventional chemotherapy, and the patient's prior treatment history may limit the intensity of therapy that can safely be delivered. Stem cell transplantation remains the most viable option for achieving long-term remission in eligible patients. 

When to Consult the Doctor for Acute Myeloid Leukemia Treatment?

Patients should seek immediate medical attention if they experience persistent and unexplained fatigue or weakness, unusual paleness, or shortness of breath even with minimal activity — all of which reflect severe anemia caused by a shortage of healthy red blood cells. Frequent or recurrent infections that do not resolve, prolonged fevers, and night sweats are also serious red flags, as they signal that the immune system is being overwhelmed by abnormal white blood cells that cannot fight infection. Additionally, easy or excessive bruising, bleeding gums, prolonged bleeding from minor cuts, or tiny red or purple spots on the skin known as petechiae indicate dangerously low platelet levels and should never be dismissed. 

Beyond these early signs, there are symptoms that suggest the disease may already be significantly advanced and require urgent evaluation without delay. These include bone or joint pain — particularly in the legs and lower back — caused by the overcrowding of leukemia cells in the bone marrow, as well as noticeable swelling in the abdomen due to an enlarged liver or spleen. Some patients may experience swollen lymph nodes, unexplained and rapid weight loss, or a general sense that something is seriously wrong with their body. In rarer but more alarming cases, neurological symptoms such as headaches, vision disturbances, or confusion may develop, indicating possible involvement of the central nervous system. At any point that these symptoms appear — particularly in combination — prompt consultation with a hematologist. 

Diagnostic Tests for Acute Myeloid Leukemia

AML can present symptoms that overlap with other hematologic conditions; a thorough and systematic diagnostic workup is essential to confirm the diagnosis, classify the disease, and assess its extent. The following tests help in the diagnostic process for AML. 

• Complete Blood Count (CBC) and Peripheral Blood Smear: CBC measures the levels of red blood cells, white blood cells, and platelets in the blood. The peripheral blood smear provides direct morphological evidence of leukemia, including the appearance of myeloblasts. 

• Bone Marrow Aspiration and Biopsy: This test extracts a sample of liquid bone marrow (aspiration) and a small core of solid bone marrow tissue (biopsy). The aspirate is examined under a microscope to assess the blast percentage — a diagnosis of AML is established when blasts make up 20% or more. 

• Cytogenetic and Molecular Testing: Cytogenetic testing (karyotyping) examines the chromosomes of leukemic cells for structural abnormalities such as translocations, deletions, or inversions. Molecular testing goes even further by identifying specific gene mutations using techniques such as PCR (polymerase chain reaction) and next-generation sequencing (NGS). 

• Flow Cytometry: This is an immunophenotyping technique that identifies and characterizes leukemia cells based on the specific proteins (antigens) expressed on their surface. 

• Imaging tests: CT scans, chest X-rays, and ultrasounds are not used to diagnose AML directly but play an important supporting role. They help assess whether the leukemia has caused organ involvement. 

Acute Myeloid Leukemia Treatment at Artemis Hospitals, Gurgaon

Acute Myeloid Leukemia is a heterogeneous hematologic malignancy characterized by the rapid clonal expansion of immature myeloid precursors in the bone marrow and peripheral blood. Its treatment remains one of the most challenging areas in oncology, demanding a multimodal approach. 

Chemotherapy (Induction and Consolidation Therapy)

This is the backbone of AML treatment and is delivered in two distinct phases. The goal of induction therapy is to achieve complete remission — meaning to kill as many leukemia cells as possible and restore normal blood cell production. The standard regimen is known as "7+3": cytarabine given continuously for 7 days combined with an anthracycline (like daunorubicin or idarubicin) for 3 days. After induction, a bone marrow biopsy is done to assess response. 

Once remission is achieved, consolidation therapy (also called post-remission therapy) follows. Its purpose is to eliminate any remaining leukemia cells that may be undetectable but could cause relapse. This typically involves high-dose cytarabine (HiDAC) given over several cycles. Without consolidation, relapse is almost certain even after a successful induction. 

Targeted Therapy and Immunotherapy

Because AML is genetically diverse, targeted therapies attack specific mutations driving the leukemia rather than broadly killing all dividing cells. 

Key targets include FLT3 mutations (present in ~30% of AML cases), treated with inhibitors like midostaurin or gilteritinib, and IDH1/IDH2 mutations, treated with enasidenib or ivosidenib. These drugs work by blocking the abnormal signals that cause leukemic cells to proliferate uncontrollably. BCL-2 inhibitor venetoclax is another important targeted agent, commonly combined with low-intensity chemotherapy (azacitidine) for older or unfit patients who cannot tolerate standard induction. 

Immunotherapy in AML is still an evolving area. Gemtuzumab ozogamicin is an antibody-drug conjugate that targets CD33 (a protein on AML cells), delivering a toxic agent directly to leukemia cells. Broader immune checkpoint inhibitors and CAR-T cell therapies are being actively investigated in clinical trials but are not yet standard of care for AML. 

Stem Cell (Bone Marrow) Transplantation

An allogeneic stem cell transplant (allo-SCT) — using a donor's cells — is the most potent anti-leukemic treatment available and offers the best chance of long-term cure for many AML patients. It is typically considered for patients with intermediate or high-risk AML, those who relapsed, or those who didn't achieve remission with chemotherapy alone. 

The process involves first giving the patient high-dose chemotherapy (and sometimes radiation) to destroy the remaining leukemia cells and suppress the immune system — this is called conditioning. Then, donor stem cells are infused and engrafted in the bone marrow, rebuilding a healthy blood and immune system. Crucially, the donor immune cells also recognize and attack any remaining leukemia cells — an effect known as graft-versus-leukemia (GvL). 

The major risks include graft-versus-host disease (GvHD), where donor immune cells attack the patient's own tissues, as well as serious infections due to the prolonged period of immunosuppression. Autologous transplants (using the patient's own cells) are less commonly used in AML and carry no GvL benefit. 

Supportive Care and Infection Management

AML and its treatment cause severe suppression of normal blood cell production (myelosuppression), making supportive care essential to keeping patients alive through treatment. 

Transfusion support — red blood cell transfusions for anemia and platelet transfusions to prevent life-threatening bleeding — is a routine part of care. Growth factors like G-CSF may be used to stimulate white blood cell recovery. Because patients are profoundly immunocompromised, infection prevention and management is critical. Bacterial, fungal (especially Aspergillus and Candida), and viral infections are major causes of morbidity and mortality in AML. Patients receive prophylactic antifungals (e.g., posaconazole), antivirals (e.g., acyclovir), and are monitored closely for fever — any febrile episode is treated as a medical emergency with broad-spectrum IV antibiotics. Isolation precautions and careful hygiene protocols are also standard. Nutritional support, pain management, and psychological support round out the holistic supportive care approach. 

What is the Recovery & Post-Treatment Care for Acute Myeloid Leukemia Patients?

Recovery after treatment for Acute Myeloid Leukemia (AML) requires patience, careful monitoring, and lifestyle adjustments. Since AML treatment can temporarily weaken immunity and energy levels, small daily choices make a big difference in healing. A clear understanding of what to do — and what to avoid — helps reduce complications and supports long-term recovery. 

Why Choose Artemis Hospitals for Acute Myeloid Leukemia Treatment in Gurgaon?

Artemis Hospitals in Gurgaon stands out as a credible choice for Acute Myeloid Leukemia (AML) treatment. The hospital is supported by expert haemato-oncologists with over 15 years of experience in treating leukemia and blood disorders, trained at premier institutions.

Artemis specializes in bone marrow transplantation — including autologous and allogeneic stem cell transplants — which are critical components of AML management. Its multidisciplinary tumor board reviews complex cases to ensure personalized, evidence-based treatment plans, supported by advanced diagnostics and technologies like PET-CT, 3T MRI, and CyberKnife.

For patients seeking quality AML care in the Delhi-NCR region, Artemis presents a well-rounded, internationally recognized option. To learn more, call +91 98004 00498.